Open AccessTo dose-adjust or not to dose-adjust: lamivudine dose in kidney impairment
Author(s) -
Karam Mounzer,
Laurence Brunet,
Christina M. Wyatt,
Jennifer S Fusco,
Vani Vannappagari,
Allan R. Tenorio,
Mark S. Shaefer,
Leigh Ragone,
Ricky Hsu,
Gregory Fusco
Publication year - 2021
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0000000000002871
Subject(s) - medicine , poisson regression , rate ratio , confidence interval , incidence (geometry) , renal function , lamivudine , cohort study , adverse effect , immunology , population , hepatitis b virus , virus , physics , environmental health , optics
To assess the risk of adverse diagnoses and laboratory abnormalities associated with a 300 or 150 mg daily dose of lamivudine (3TC) initiated by people with HIV (PWH) with an estimated glomerular filtration rate (eGFR) between at least 30 and 49 ml/min per 1.73 m2 or less.